Samsung Biologics unveils $897 mln manufacturing deals for Pfizer
South Korea's Samsung Biologics announced on Tuesday two deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant. The latest orders bring this year's combined tally of orders from Pfizer to $1.08 billion, Samsung Biologics said in a statement.